Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Analysis Group, Inc.

Boston, Massachusetts, 02199, United States

About this study

The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients with PC will be recruited to complete the online DCE survey.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Physician inclusion criteria

The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
The physician has cared for at least ten nmHSPC patients in the past year.
The physician has experience prescribing NHT and ADT. Patient inclusion criteria
The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.

Exclusion criteria

Physician exclusion criteria

None Patient exclusion criteria
The patient is castration resistant.
The patient has metastatic PC.

Treatment and study plan

No intervention

Other

No investigational drug will be administered to participants in this study.

Primary outcomes

Patients' Preference weights for different treatment attributes

Time frame: Up to 1 day

Preference data will be collected via online survey questionnaires designed using DCE method.
Patients' Overall Preference for a specific treatment profile (NHT +/- ADT or ADT monotherapy)

Time frame: Up to 1 day

Preference data will be collected via online survey questionnaires designed using DCE method.

Sponsors and collaborators

Lead sponsor

Astellas Pharma Global Development, Inc.

Industry

Registry information

Official study title

Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Jul 15, 2024
Registry last updated: May 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed